Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

Caffo, Orazio; Giorgi, Ugo De; Fratino, Lucia; Adami, Daniele; Zagonel, Vittorina; Facchini, Gaetano; Gasparro, Donatello; Ortega, Cinzia; Tucci, Marco; Verderame, Francesco; Campadelli, Enrico; Re, Giovanni Lo; Procopio, Giuseppe; Sabbatini, Roberto; Donini, Maddalena; Morelli, Franco; Sartori, Donata; Zucali, Paolo Andrea; Carrozza, Francesco; D’Angelo, Alessandro; Vicario, Giovanni; Massari, Francesco; Santini, Daniele; Sava, Teodoro; Messina, Caterina; Fornarini, Giuseppe; Torre, L. La; Ricotta, Riccardo; Aieta, Michele; Mucciarini, Claudia; Zustovich, Fable; Macrini, Sveva; Burgio, Salvatore Luca; Santarossa, Sandra; D’Aniello, Carmine; Basso, Umberto; Tarasconi, Sara; Cortesi, Enrico; Buttigliero, Consuelo; Ruatta, Fiorella; Veccia, Antonello; Conteduca, Vincenza; Maines, Francesca; Galligioni, Enzo

doi:10.1016/j.eururo.2014.10.014

Cited by 75 publications

(52 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…102 It should be mentioned that ASIs might have some effect after progression on cabazitaxel, and patients whose health status descends to "frail" as a result of progression of the disease could still benefit from subsequent treatment with ASIs. 103 Radium-223 is considered an appropriate option for patients with symptomatic bone and non-visceral metastases. Comparable toxicity when using radium-223 with other ASIs was reported, 104 and a preliminary report from a phase 1/2a study showed that radium-223 with docetaxel had greater percentage decline in total alkaline phosphatase and in bone formation markers, bone alkaline phosphatase and P1NP, than the treatment with only docetaxel.…”

Section: Cross-resistance Between Classes Of Agentsmentioning

confidence: 99%

Current treatment strategies for advanced prostate cancer

et al. 2017

View full text Add to dashboard Cite

During the past decade, treatment strategies for patients with advanced prostate cancer involving stage IV (T4N0M0, N1M0 or M1) hormone-sensitive prostate cancer and recurrent prostate cancer after treatment with curative intent, as well as castration-resistant prostate cancer, have extensively evolved with the introduction and approval of several new agents including sipuleucel-T, radium-223, abiraterone, enzalutamide and cabazitaxel, all of which have shown significant improvement on overall survival. The appropriate use of these agents and the proper sequencing of these agents are still not optimized. The results of several recently reported randomized controlled trials and retrospective studies could assist in developing a treatment strategy for advanced prostate cancer. In addition, prospective studies and molecular characterization of tumors to address these issues are ongoing.

show abstract

Section: Cross-resistance Between Classes Of Agentsmentioning

confidence: 99%

Current treatment strategies for advanced prostate cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, these finding might not apply to DCT considering that men receiving AA before DCT are more likely to progress on DCT and less likely to achieve a PSA response that AA-naïve patients [70,[74][75][76][77][78]. In addition, large multicenter studies failed to show any signifcant difference in the clinical outcomes of third line treatment with AA, ENZ or CZT regardless of previous therapy delivered [79], whereas in a less advanced treatment setting, the prospective evidence from the recent TERRAIN trial support the use of ENZ rather than bicalutamide in patients with asymptomatic or midly symptomatic CRPC [80]. Supplemental Figure 3 shows options of targeting CRPC according to the activation of AR.…”

Section: Sequential Administration Of New Agents In Crpcmentioning

confidence: 86%

A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer

Seisen

Rouprêt

Gomez

et al. 2016

Cancer Treatment Reviews

View full text Add to dashboard Cite

Hormone-naïve prostate cancer and its castration-resistant state (CRPC) are clinically and genetically heterogeneous diseases. From initiation of prostate carcinogenesis to its evolution towards therapeutic resistance, various combinations of genetic and epigenetic events occur.Schematically, progression to CRPC could be divided in two distinct pathways, either dependent or independent of the androgen receptor activity. Nevertheless, because the better knowledge of the genetic landscape of CRPC is under way, limited clinical applications are available at the moment, underlying the usefulness of prognostic and predictive biomarkers in daily practice. Despite the promising prognostic value of circulating tumor cells, no biomarker has been currently validated as a surrogate for overall survival in CRPC patients.Inversely, considerable interest has been generated with the recent finding of the splice variant AR-V7 that allows to predict resistance to abiraterone acetate and enzalutamide.However, other predictive biomarkers would be necessary to accurately guide personalized sequencing of CRPC treatment, which now includes numerous possibilities based on the six validated drugs, without accounting for those currently under investigation in the ongoing randomized controlled trials. As a consequence, only rational sequencing, which consists in choosing an agent that is not expected to have cross-resistance with previous therapy, can be currently advised.

show abstract

“…Since the advent of abiraterone and enzalutamide, the use of cabazitaxel has declined. Intriguingly, some but not all retrospective studies suggest that cabazitaxel followed by androgen axis inhibitors might lead to improved outcomes compared with androgen axis inhibitors followed by cabazitaxel [5,6]. Another piece in the puzzle is provided by retrospective studies suggesting that cabazitaxel may retain substantial activity even after docetaxel and novel androgen inhibitors, while docetaxel appears to show poorer activity after androgen inhibitors [7].…”

mentioning

confidence: 99%

“…Then, in 2012, Rolle et al [5] described the sliding technique, a modification of the circumferential graft that consists of a double dorsal-ventral patch and should therefore…”

mentioning

confidence: 99%

Cabazitaxel for the therapy of metastatic castration‐resistant prostate cancer in the aftermath of the CHAARTED trial

Pal

Sonpavde

2015

BJU International

View full text Add to dashboard Cite

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study

Abstract: It is debated which sequence of treatments to adopt after docetaxel. Our data do not support the superiority of any of the three new agents in third-line treatment, regardless of the previously administered new agent.

Cited by 75 publications

References 23 publications

Current treatment strategies for advanced prostate cancer

Current treatment strategies for advanced prostate cancer

A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer

Cabazitaxel for the therapy of metastatic castration‐resistant prostate cancer in the aftermath of the CHAARTED trial

Contact Info

Product

Resources

About